Physician profile
Ying Fu
NPI 1982239497
$4,714.32
in general payments reported to CMS, 2019-2025
20 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,645 · 2022: $1,216 · 2023: $333 · 2024: $978 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,420.16 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $974.69 | 2021-2023 | Rybelsus, Ozempic |
| Amgen INC. | $762.50 | 2021-2023 | Repatha, Prolia, Evenity |
| Glaxosmithkline, LLC. | $329.88 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $193.99 | 2023-2024 | |
| Abbvie INC. | $134.64 | 2025 | |
| Amarin Pharma, INC. | $129.03 | 2021-2022 | |
| Dexcom, INC. | $125.82 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $125.00 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.27 | 2024 | Xifaxan |
| Lilly USA, LLC | $109.33 | 2021-2025 | Mounjaro |
| Gilead Sciences, INC. | $92.23 | 2022-2024 | |
| Upsher-Smith Laboratories LLC | $40.99 | 2021 | |
| Lundbeck LLC | $32.37 | 2024 | Rexulti |
| Pfizer INC. | $31.43 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.92 | 2023 | Jardiance |
| Edwards Lifesciences Corporation | $19.78 | 2024 | Sapien 3 Ultra Resilia |
| Currax Pharmaceuticals LLC | $14.22 | 2024 | Onzetra Xsail, Contrave |
| Eisai INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.